Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher McDaniels

Internal Medicine Raleigh, NC Medical Doctor

NPI 1417918814 CMS profile 290761

3100 Blue Ridge Rd Ste 300, Raleigh, NC 27612

Open in the dashboard

General payments

$10,354

613 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher McDaniels of Raleigh, NC is reported in the CMS Open Payments database as having received $10,354 across 613 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,782 97
2024 General $1,674 95
2023 General $2,361 120
2022 General $1,523 88
2021 General $1,005 62
2020 General $363 25
2019 General $1,645 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher McDaniels
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher McDaniels were reported at $1,782. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher McDaniels Internal Medicine median Middle half National median
2019 $1,645 $159 $48–$570 $163
2020 $363 $119 $33–$402 $114
2021 $1,005 $135 $37–$521 $132
2022 $1,523 $141 $42–$496 $149
2023 $2,361 $149 $45–$519 $160
2024 $1,674 $154 $47–$537 $164
2025 $1,782 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,524 93 payments
  2. AbbVie, Inc. $1,488 81 payments
  3. Lilly USA, LLC $944 65 payments
  4. Pfizer Inc. $780 57 payments
  5. GlaxoSmithKline, LLC. $661 43 payments
  6. AstraZeneca Pharmaceuticals LP $588 38 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $374 19 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $339 22 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $284 17 payments
  10. Amgen Inc. $241 16 payments
  11. Other $3,130 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,334 610 payments
  2. Education $20 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $983 62 payments
  2. RYBELSUS $822 49 payments
  3. UBRELVY $792 41 payments
  4. QULIPTA $576 29 payments
  5. MOUNJARO $485 27 payments
  6. TRELEGY ELLIPTA $436 27 payments
  7. FARXIGA $402 25 payments
  8. NURTEC ODT $395 27 payments
  9. Wegovy $370 19 payments
  10. VRAYLAR $299 17 payments
  11. Other $8,088 493 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

5,131

Median for Internal Medicine: 777

Drug cost

$339,041

Median for Internal Medicine: $73,373

Branded share of claims

18.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 52 $72,531
Ozempic Semaglutide Brand 53 $60,950
Eliquis Apixaban Brand 69 $60,221
Farxiga Dapagliflozin Propanediol Brand 27 $27,729
Xarelto Rivaroxaban Brand 21 $19,845
Mounjaro Tirzepatide Brand 15 $15,047
Trintellix Vortioxetine Hydrobromide Brand 11 $9,892
Synthroid Levothyroxine Sodium Brand 47 $4,746
Rosuvastatin Calcium Generic 220 $3,451
Metoprolol Succinate Generic 186 $3,101

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$83,546

Of which drugs: $6,800

Medicare patients

231

Average age 74

Services billed

3,472

122 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 42%
Ischemic heart disease 22%
Diabetes 18%
Atrial fibrillation 16%
Cancer 16%
Chronic kidney disease 13%
Depression 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 31 31 $2,381
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 11 11 $259

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $123
$123 15 —
UBRELVY
  • AbbVie, Inc. $94
$94 — —
RYBELSUS
  • Novo Nordisk Inc $93
$93 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $87
$87 — —
Wegovy
  • Novo Nordisk Inc $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

613 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record